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poor adherence to diabetes medications (Morisky adherence score < 6). The propor-
tion of individuals with poor adherence rather than good adherence, was higher 
among individuals with high B-IPQ scores for illness consequences (65%, p < 0.006), 
illness symptoms (67%, p < 0.008), emotional effect of illness (63%, p < 0.012) and 
among those with low B-IPQ scores for illness understanding (76%, p < 0.008). Illness 
beliefs regarding how well treatment can control diabetes (0.23, p < 0.007), concerns 
about diabetes (0.21, p < 0.017) and understanding of the illness (0.20, p < 0.002), 
had positive correlations with medication adherence. CONCLUSIONS: Illness beliefs 
were associated with adherence to diabetes medication and may be useful in assessing 
patients’ potential for adherence problems.
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OBJECTIVES: Compliance with treatment is a key factor for successful treatment of 
chronic conditions like type 2 diabetes mellitus. Once-daily extended-release glipizide 
(GXL) has been showing more appealing in patient compliance. However, the data 
on comparison of GXL with other oral glucose-lowering drugs concerning compliance 
is limited. We tried to assess the compliance to GXL treatment for type 2 diabetes 
mellitus when compared with immediate-release glipizide(GIR). METHODS: We 
searched Medline, EMBASE, Cochrane Library, and the Chinese Biomedical database 
from their inception to end-Dec. 2009, as well as traced the reference lists. Rand-
omized or non-randomized studies that reported medication compliance/adherence or 
persistence when using GXL versus GIR for treating the type 2 diabetes mellitus were 
included. Four reviewers judged trial eligibility and extracted data independently. We 
pooled trial data using the random-effect model and explored heterogeneity by using 
pre-speciﬁed variables. RESULTS: A total of 9 published studies (n = 13 512) were 
included. GXL resulted in a 7% increase in compliance when compared with GIR 
(RD = 0.07, 95%CI = 0.06 to 0.08). The subgroup analyses showed that GXL 
increased patient compliance by 7% when compared with GIR in 4 retrospective 
database analyses (n = 13 250, RD = 0.07, 95%CI = 0.05 to 0.10) and showed no 
difference in 5 randomized trials (n = 262, RD = 0.01, 95%CI = −0.03 to 0.05). There 
was no signiﬁcant difference in patient compliance between ﬁxed-dose GXL and GIR 
(RD = 0.05, 95%CI = −0.01 to 0.11); however, the titrated-dose GXL signiﬁcantly 
increased patient compliance by 6% (RD = 0.06, 95%CI = 0.03 to 0.09). When 
compared to GIR, GXL in long-term treatments (equal to or more than 1 year) 
increased patient compliance by 7% (RD = 0.07, 95%CI = 0.05 to 0.08), while no 
signiﬁcant difference in short-term treatments (less than 1 year). CONCLUSIONS: 
When compared to immediate-release glipizide, extended-release glipizide could 
increase long-term patient compliance in retrospective database studies, while the 
increase in the short-term compliance to GXL was not observed.
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OBJECTIVES: The aim of this study was to measure adherence and persistence of 
oral hypoglycemic agents among Type II Diabetes patients and to examine differences 
in adherence and persistence by type of oral hypoglycemic agent (OHA) and demo-
graphic characteristics. METHODS: A retrospective analysis was conducted using 
Mississippi Medicaid claims data for 2002 through 2004. After a 6-month wash-out 
period, patients beginning OHA monotherapy were classiﬁed as taking sulfonylurea, 
metformin hydrochloride, thiazolidinediones (TZDs) or other. Patients were observed 
until they had a lapse in Medicaid coverage or discontinued mono therapy on the 
original OHA. A reﬁll gap > 2*day supply was considered to be discontinuation of 
therapy. Persistence was measured as percent of patients remaining on therapy at the 
end of each month. Adherence rates, proportion of days covered (PDC), were com-
puted for each 90 day period that patients remained on therapy after the ﬁrst ﬁll date. 
RESULTS: A total of 6,206 diabetic patients > 18 years of age were included with 
49% on sulfonylurea, 29% on metformin and 16% on TZDs. After 6 months persist-
ence was signiﬁcantly higher for sulfonylurea and TZD (46% and 45% at 12 months) 
compared to metformin (42%). Persistence dropped to around 25% by 18 months. 
Mean adherence rates for Q1 (ﬁrst 90-day period) were 80% for metformin, 82% for 
sulfonylurea, and 85% for TZD. Mean adherence rates dropped in Q2 to 68% for 
metformin, 71% for sulfonylurea, and 72% for TZD and remained relatively stable 
for patients remaining on therapy for up to 2 years. CONCLUSIONS: The rapid drop 
in persistency for monotherapy OHAs is not surprising since diabetic regimens are 
frequently modiﬁed. Although average adherence rates for all types of monotherapy 
OHAs remained steady after Q2, the average rate was below 80%. These results 
indicate that new OHA patients need extra counseling about the importance of 
adherence.
PDB44
A SYSTEMATIC REVIEW OF ADHERENCE, QUALITY OF LIFE AND 
MEDICAL COSTS IN FIXED-DOSE COMBINATION REGIMENS IN 
DIABETES
Hutchins V1, Krishnarajah G2, Fleurence R1
1United BioSource Corp., Bethesda, MD, USA, 2Bristol-Meyers Squibb, Plainboro, NJ, USA
OBJECTIVES: Oral antidiabetics(OAD) have comparable safety and efﬁcacy in ﬁxed-
dose combination therapies(FDCT) and loose-pill combination therapies(LPCT) for 
patients with Diabetes Mellitus Type II(T2DM). To evaluate FDCT outcomes besides 
safety and efﬁcacy a systematic review was conducted. METHODS: Searches of 
Medline/Embase databases from 1998–2009 used predeﬁned search terms: “ﬁxed-dose 
combination”, “loose-dose combination” and “diabetes”. Additionally, we reviewed 
abstracts from ISPOR, EASD and ADA meetings. T2DM studies were included if they 
reported adherence, patient reported outcomes(PRO), costs, resource use or cost-
effectiveness. RESULTS: Seventeen studies met the search criteria. Seven studies 
reported adherence. Adherence was 10–13% higher for FDCT than LPCT in patients 
starting combination therapy(two studies). Adherence decreased 1.5% and 10.0% 
when switching from monotherapy to combination therapy for FDCT and LPCT, 
respectively(one study, P < 0.001). Three studies report adherence when switching 
from LPCT to FDCT versus remaining on LPCT. Switching to FDCT increased adher-
ence 3.5%–12.4%, while remaining on LPCT changed adherence −1.5% to 5.0%(P 
< 0.005). For patients newly initiating OAD medication, one study found no adherence 
advantage for FDCT, compared with monotherapy or LPCT. Five randomized con-
trolled trials(RCTs) reported treatment satisfaction. Four publications found patients 
preferred FDCT using the Diabetes Treatment Satisfaction Questionnaire(DTSQ). One 
publication found improved satisfaction for one DTSQ subscale only. Five abstracts 
reported economic outcomes. Two abstracts determined patients on FDCT use fewer 
health care resources and decreased direct health care costs by $169 and $255 patient 
per month than LPCT(P < 0.05). Two cost effectiveness models determined clinical 
beneﬁts from clinical trials translate into cost savings and increased life expectancy. 
One budget impact model reported minimal budget impact. CONCLUSIONS: Com-
pared to T2DM patients on LPCT, FDCT users may have better adherence, improved 
satisfaction, and lower direct medical costs. Overall, data for economic implications 
are limited. Further studies are warranted to further deﬁne potential beneﬁt of FDCT 
in T2DM, a prevalent and costly disease.
PDB45
ASSOCIATION BETWEEN HEALTH INSURANCE PLAN TYPE AND 
MEDICATION POSSESSION RATIOS IN ADULT WORKING AGE 
PATIENTS WITH TYPE 2 DIABETES MELLITUS
Kirk JR1, Campbell C1, Fonseca V1, Zhao Y1, Olukotun AY2, Shi L1
1Tulane University, New Orleans, LA, USA, 2CarioVax, LLC, Princeton, NJ, USA
OBJECTIVES: The objective of this research project was to evaluate the effect of 
health insurance plan type on anti-diabetic medication adherence as measured by 
medication possession ratios (MPR > 0.80: good MPR) for oral medications. 
METHODS: The data source for this research project was the 2000–2001 MarketScan 
dataset, which is comprised of administrative claims data for over 2.5 million privately 
insured individuals in the United States. MPR was deﬁned as the sum of days 
supply each anti-diabetic medication divided by the number of days between the ﬁrst 
and last prescription ﬁll dates plus the number of days for the last reﬁll. RESULTS: 
The odds of having a good MPR for oral anti-diabetic medications were evaluated 
using multiple logistic regression models controlled for insurance plan type plus 
demographic and clinical characteristics of the target patient population. A propensity 
score analysis was done using a stratiﬁcation approach to further control for selection 
bias. The proportion of patients with MPR ≥80% was 68.2%. CONCLUSIONS: 
Patients in capitated plans were more likely to have good MPR compared to FFS, PPO 
and POS plan types (odds ratios: 0.75, p < 0.001; 0.81, p < 0.001; 0.81, p < 0.001, 
respectively). This relationship remained in all quintiles of the propensity score 
analysis.
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OBJECTIVES: 1. To determine the pattern of adherence to statins among the diabetes 
patients at a self-insured university. 2. To determine the effect of independent variables 
[age, gender, co-payment, and campus location (main campus/health science campus)] 
on adherence to statins. METHODS: Pharmacy claims data was used to identify 
patients using both diabetes and statin drugs during the study period between January 
1, 2006 and June 2, 2008. Adherence to statins was calculated at regular observation 
periods using Medication possession ratio (MPR). Patients with MPR ≥ 80% were 
considered adherent. Patients with MPR < 80% were considered non-adherent. Logis-
tic regression was used to study the effect of independent variables on adherence to 
statins. RESULTS: Two hundred and ninety-ﬁve patients were included in the study. 
The mean age of the patients was 55.09 ± 9.30 years. The mean MPR of statins was 
0.76, 0.70, and 0.68 in the 6, 12, and 24 months observation periods respectively. 
During the ﬁrst six months, about 58% of patients were adherent to statins with MPR 
≥ 0.80. About 51% and 48% of patients were adherent to statins during the 12 and 
24 months observation periods. Age was signiﬁcantly positively associated with adher-
ence to statins (Odds ratio, 1.04; 95% CI, 1.01–1.07). Males were 48.3% more likely 
